Relationships among hyperuricemia, metabolic syndrome, and endothelial function

American Journal of Hypertension

Volumn 24, Issue 7, 2011, Pages 770-774

  Tomiyama, Hirofumi ^a   Higashi, Yukihito ^b   Takase, Bonpei ^c   Node, Kohichi ^d   Sata, Masataka ^e   Inoue, Teruo ^f   Ishibashi, Yutaka ^g   Ueda, Shinichiro ^h   Shimada, Kenei ⁱ   Yamashina, Akira ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d SAGA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g SHIMANE UNIVERSITY   (Japan)

^h UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

ⁱ Osaka Ekisaikai Hospital   (Japan)

Author keywords

blood pressure; endothelial function; hypertension; hyperuricemia; metabolic syndrome; risk factors; uric acid

Indexed keywords

URIC ACID;

ADULT; ARTICLE; BLOOD FLOW; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; HUMAN; HYPERTENSION; HYPERURICEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL; VASODILATATION;

ADULT; BRACHIAL ARTERY; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERURICEMIA; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; URIC ACID; VASODILATION;

EID: 79959331818     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.55     Document Type: Article

References (28)

1. Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis 2009; 202:11-17.
2. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61:885-892.
3. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008; 58:623-630. (Pubitemid 351294901)
4. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis 2005; 183:147-155.
5. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115:1285-1295. (Pubitemid 46594773)
6. Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF Jr, Lehman BT, Fan S, Osypiuk E, Vita JA. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004; 109:613-619. (Pubitemid 38198868)
7. Tomiyama H, Matsumoto C, Yamada J, Teramoto T, Abe K, Ohta H, Kiso Y, Kawauchi T, Yamashina A. The relationships of cardiovascular disease risk factors to flow-mediated dilatation in Japanese subjects free of cardiovascular disease. Hypertens Res 2008; 31:2019-2025.
8. Erdogan D, Gullu H, Caliskan M, Yildirim E, Bilgi M, Ulus T, Sezgin N, Muderrisoglu H. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005; 59:1276-1282. (Pubitemid 43904496)
9. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004; 94:932-935. (Pubitemid 39349561)
10. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47:1093-1100.
11. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54:3252-3257. (Pubitemid 43334382)
12. Hamburg NM, Larson MG, Vita JA, Vasan RS, Keyes MJ, Widlansky ME, Fox CS, Mitchell GF, Levy D, Meigs JB, Benjamin EJ. Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham Offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol 2008; 101:82-88.
13. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811-1821.
14. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265. (Pubitemid 34084631)
15. The Committee of Establishing the Definition of the Diagnosis of Metabolic Syndrome in Japan. J Jpn Soc Int Med 2005; 94:188-203 (In Japanese).
16. Esen AM, Akcakoyun M, Esen O, Acar G, Emiroglu Y, Pala S, Kargin R, Karapinar H, Ozcan O, Barutcu I. Uric acid as a marker of oxidative stress in dilatation of the ascending aorta. Am J Hypertens 2011; 24:149-154.
17. Vlachopoulos C, Xaplanteris P, Vyssoulis G, Bratsas A, Baou K, Tzamou V, Aznaouridis K, Dima I, Lazaros G, Stefanadis C. Association of Serum Uric Acid Level With Aortic Stiffness and Arterial Wave Reflections in Newly Diagnosed, Never-Treated Hypertension. Am J Hypertens 2011; 24: 33-39.
18. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67:1739-1742. (Pubitemid 40577708)
19. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35:746-751. (Pubitemid 30165320)
20. Yiginer O, Ozcelik F, Inanc T, Aparci M, Ozmen N, Cingozbay BY, Kardesoglu E, Suleymanoglu S, Sener G, Cebeci BS. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol 2008; 97:334-340.
21. Tavil Y, Kaya MG, Oktar SO, Sen N, Okyay K, Yazici HU, Cengel A. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis 2008; 197:159-163. (Pubitemid 351273235)
22. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005; 25:1038-1044. (Pubitemid 40627852)
23. Kawamoto R, Tomita H, Oka Y, Ohtsuka N. Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intern Med 2006; 45:605-614. (Pubitemid 43880913)
24. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54:2129-2138.
25. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42:1149-1160. (Pubitemid 37188333)
26. Ter Avest E, Stalenhoef AF, de Graaf J. What is the role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction? Clin Sci 2007; 112:507-516. (Pubitemid 46762012)
27. Kasprzak JD, Klosinska M, Drozdz J. Clinical aspects of assessment of endothelial function. Pharmacol Rep 2006; 58 Suppl:33-40.
28. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-3421.